This data is valuable because it captures effects in broader populations than clinical trials, including people with comorbidities, those taking multiple medications, and those using doses or schedules that differ from trial protocols
WorldatWork & IFEBP, 2024) The Data Explained: GLP-1 Coverage Adoption Coverage for GLP-1s among large employers (500+ employees) grew from 41% in 2023 to 44% in 2024, with projections showing continued expansion as employers weigh cost versus employee demand (Intercept Health, HR Dive)
Administering sermorelin and ipamorelin in conjunction may produce synergies for enhanced results compared to administering either compound alone
After a short rest, we will take a night tour and enter the forest to observe and listen for insects, bats, toads and perhaps an occasional encounter with other nocturnal mammals
Bar-Peled, L., Schweitzer, L
Gregory GA et al